LSD

Effects

visual distortionsa sense of childlike wonderbrightening of colorsracing thoughtshue shiftseuphoriaanxietyconfusion TS

Overview

Lysergic acid diethylamide (also known as Lysergide, LSD-25, LSD, L, Lucy, and Acid) is a classical psychedelic substance of the lysergamide class. It is perhaps the most researched and culturally influential psychedelic substance, as well as the prototypal lysergamide. The mechanism of action is not fully known, although serotonin binding activity is thought to be involved.[1] PW

LSD is a popular psychedelic with a relatively long history of use and research, and as such is known to be relatively safe despite its extremely high potency. It is the archetypical psychedelic to which all others are compared, and remains in popular usage.[2–17] TS

Lysergic acid diethylamide, commonly known as LSD (from German Lysergsäurediethylamid) and by the nicknames acid and Lucy, is a semisynthetic psychedelic drug derived from ergot, known for its potent psychological effects.[18] WP

LSD taken orally has an onset of action of 0.4 to 1.0 hours and a duration of 7 to 12 hours. In recreational settings it is commonly administered via tabs of blotter paper. LSD is extremely potent, with noticeable effects at doses as low as 20 micrograms and is sometimes taken in even smaller amounts for microdosing. Despite widespread use, no fatal human overdoses have been documented. LSD is mainly used recreationally or for spiritual purposes. LSD can cause mystical experiences. LSD exerts its effects primarily through high-affinity binding to several serotonin receptors, especially the serotonin 5-HT2A receptor, and to a lesser extent dopamine and adrenergic receptors. Neuroimaging studies indicate that LSD reduces the efficacy of thalamo-cortical information filtering (producing sensory overload), decreases oscillatory power within the default mode network, and flattens hierarchical organization of large-brain activity. At higher doses, it can induce visual and auditory hallucinations, ego dissolution, and anxiety. LSD use can cause hallucinogen-induced psychotic disorder where paranoia and delusions persist beyond the initial effects of the drug. LSD may lead to persistent visual disturbances known as hallucinogen persisting perception disorder (HPPD).[1][19–32] WP

Swiss chemist Albert Hofmann first synthesized LSD in 1938 and discovered its potent psychedelic effects in 1943 after accidental ingestion. It became widely studied in the 1950s and 1960s. The drug was initially explored for psychiatric use due to its structural similarity to serotonin and safety profile. It was used experimentally in psychiatry for treating alcoholism and schizophrenia. By the mid-1960s, LSD became central to the youth counterculture in places like San Francisco and London, influencing art, music, and social movements through events like Acid Tests and figures such as Timothy Leary, Owsley Stanley and Michael Hollingshead. Its psychedelic effects inspired distinct visual art styles and musical innovations, and caused a lasting cultural impact. However, its association with the counterculture movement of the 1960s led to its classification as a Schedule I drug in the United States in 1970. It was also listed as a Schedule I controlled substance by the United Nations in 1971 and remains without approved medical uses.[23][33–36] WP

Despite its legal restrictions, LSD remains influential in scientific and cultural contexts. Research on LSD declined due to cultural controversies by the 1960s, but has resurged since 2009. In 2024, the United States Food and Drug Administration designated LSD (code name MM120 or DT120) as a breakthrough therapy for generalized anxiety disorder. As of 2017, about 10% of people in the United States had used LSD at some point, with 0.7% having used it in the past year. Usage rates have risen, with a 56.4% increase in adult use in the United States from 2015 to 2018.[37][38][39] WP

History

History

LSD was first synthesized on November 16, 1938 by Swiss chemist Albert Hofmann at the Sandoz Laboratories in Basel, Switzerland as part of a large research program searching for medically useful ergot alkaloid derivatives.[65][66] WP

LSD was synthesised from lysergic acid, a chemical derived from the hydrolysis of the alkaloid ergotamine, which can be found in the grain-infecting fungus ergot. It was the 25th substance of various lysergamides that Hofmann synthesized from lysergic acid while trying to develop a new analeptic, hence its alternate name, LSD-25.[23][33] WP

LSD's psychedelic properties were discovered 5 years later when Hofmann himself accidentally ingested an unknown quantity of the chemical. The first intentional ingestion of LSD occurred on April 19, 1943, when Hofmann ingested 250 μg of LSD. He said this would be a threshold dose based on the doses of other ergot alkaloids; however, Hofmann found the effects to be much stronger than he anticipated. Information about synthesizing LSD was first published in scientific literature by Hofmann and his colleague, psychiatrist Werner Stoll in 1943; a description of LSD's hallucinogenic effects was later published by Stoll in 1947.[67–74] WP

Historical pharmaceutical production and distribution

Sandoz Laboratories introduced LSD as a psychiatric drug in 1947, marketing it as a psychiatric panacea which could serve "as a cure for everything from schizophrenia to criminal behavior, 'sexual perversions', and alcoholism." Sandoz also sent the drug for free to researchers investigating its effects. In 1963, the Sandoz patents on LSD expired and the Czech company Spofa began to produce the substance. Sandoz stopped the production and distribution in 1965.[68][75][76] WP

History of cultural impact

The use of LSD was most widespread from the 1960s through the 1980s. In the 1960s, LSD and other psychedelics were adopted by and became synonymous with the Hippie counterculture movement due to their perceived ability to expand consciousness. This resulted in LSD being viewed as a cultural threat to American values and the Vietnam War effort, and it was designated as a Schedule I (illegal for medical as well as recreational use) substance in 1968. It was listed as a Schedule I controlled substance by the United Nations in 1971 and currently has no approved medical uses.[23][36] WP

Several figures, including Aldous Huxley, Timothy Leary, and Al Hubbard, had begun to advocate the consumption of LSD as it became central to the counterculture of the 1960s. In the early 1960s, the use of LSD and other hallucinogens was advocated by new proponents of consciousness expansion such as Leary, Huxley, Alan Watts and Arthur Koestler, and, according to historians, they profoundly influenced the thinking of the new generation of youth.[77–80] WP

Legal status

• Internationally, the UN 1971 Convention on Psychotropic Substances requires its parties to prohibit LSD. Hence, it is illegal in all parties to the convention, which includes the United States, Australia, New Zealand, and most of Europe. PW
• Medical and scientific research with LSD in humans is permitted under the 1971 UN Convention, although has been reported to be difficult to actually carry out in practice.[81] PW
• Australia: LSD is considered a Schedule 9 prohibited substance in Australia under the Poisons Standard. A Schedule 9 substance is a substance which may be abused or misused and the manufacture, possession, sale or use of is prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities. Possession of under 5 doses of LSD is decriminalized in the Australian Capital Territory (ACT) as of October 28, 2023.[82][83] PW
• Austria: LSD is illegal to possess, produce and sell under the Addictive Substances Act (Suchtmittelgesetz).[81][84] PW
• Brazil: Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.[85] PW
• Canada: LSD is a Schedule III controlled substance in Canada.[86] PW
• Croatia: LSD is a controlled substance.[87] PW
• Czech Republic: In 2010, the possession of 5 tabs of LSD has been decriminalized. Anybody possessing less than this amount may be charged for a misdemeanor or receive a warning from police.[88] PW
• Denmark: LSD is a Category A controlled substance in Denmark.[89] PW
• Germany: LSD is controlled under Schedule I of the Narcotics Act (Anlage I BtMG), former Opium Act (Opiumgesetz) as of February 25, 1967. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.[90][91][92] PW
• Italy: LSD is a Schedule I (Tabella I) controlled substance.[93] PW
• Japan: LSD is classified as a narcotic under the Narcotic and Psychotropic Drugs Control Act (麻薬及び向精神薬取締法).[94] PW
• Latvia: LSD is a Schedule I controlled substance in Latvia.[95] PW
• Luxembourg: LSD is a prohibited substance.[96] PW
• The Netherlands: LSD is classified as a List I (Lijst 1) controlled substance under the Opium Law (Opiumwet).[97] PW
• Norway: LSD is classified as a narcotic.[98] PW
• Portugal: LSD is illegal to produce, sell or trade in Portugal. However since 2001, individuals found in possession of small quantities (up to 500 µg) are considered sick individuals instead of criminals. The substance is confiscated and the suspects may be forced to attend a dissuasion session at the nearest CDT (Commission for the Dissuasion of Drug Addiction) or pay a fine, in most cases.[99] PW
• Russia: LSD is a List I (список I) contolled substance. It is illegal to possess, produce and sell.[100] PW
• Switzerland: LSD is a controlled substance specifically named under Verzeichnis D.[101] PW
• Sweden: LSD is a Schedule I (Förteckning I) controlled substance. The Swedish supreme court concluded in 2018 that possession of processed plant material containing a significant amount of DMT is illegal. However, possession of unprocessed such plant material was ruled legal.[102] PW⚠ PsychonautWiki itself has flagged this text: citation needed.
• United Kingdom: LSD is a Class A controlled substance in the United Kingdom.[103] PW
• United States: LSD is a Schedule I controlled substance under the Controlled Substances Act of 1970. This means it is illegal to manufacture, buy, possess, process, or distribute without a license from the Drug Enforcement Administration (DEA).[104] PW
• Poland: LSD is illegal to own, produce and sell under "Wykaz środków odurzających i substancji psychotropowych" and is grouped in "I-P"[105] PW

Historical legality and modern-day usage in the united states

On October 24, 1968, possession of LSD was made illegal in the United States. The last FDA approved study of LSD in patients ended in 1980, while a study in healthy volunteers was made in the late 1980s. Legally approved and regulated psychiatric use of LSD continued in Switzerland until 1993.[106][107] WP

As of 2017, about 10% of people in the United States have used LSD at some point in their lives, while 0.7% have used it in the last year. The use of LSD among US adults increased by 56.4% from 2015 to 2018. In November 2020, Oregon became the first US state to decriminalize possession of small amounts of LSD after voters approved Ballot Measure 110.[38][39][108] WP

Counterculture

By the mid-1960s, the youth countercultures in California, particularly in San Francisco, had widely adopted the use of hallucinogenic drugs, including LSD. The first major underground LSD factory was established by Owsley Stanley. Around this time, the Merry Pranksters, associated with novelist Ken Kesey, organized the Acid Tests, events in San Francisco involving LSD consumption, accompanied by light shows and improvised music. Their activities, including cross-country trips in a psychedelically-decorated bus and interactions with major figures of the beat movement, were later documented in Tom Wolfe's The Electric Kool-Aid Acid Test (1968).[109–112] WP

In San Francisco's Haight-Ashbury neighborhood, the Psychedelic Shop was opened in January 1966 by brothers Ron and Jay Thelin to promote the safe use of LSD. This shop played a significant role in popularizing LSD in the area and establishing Haight-Ashbury as the epicenter of the hippie counterculture. The Thelins also organized the Love Pageant Rally in Golden Gate Park in October 1966, protesting against California's ban on LSD.[113][114] WP

A similar movement developed in London, led by British academic Michael Hollingshead, who first tried LSD in America in 1961. After experiencing LSD and interacting with notable figures such as Aldous Huxley, Timothy Leary, and Richard Alpert, Hollingshead played a key role in the famous LSD research at Millbrook before moving to New York City for his experiments. In 1965, he returned to the UK and founded the World Psychedelic Center in Chelsea, London.[115] WP

Blotter art

Blotter art is an art form printed on perforated sheets of absorbent blotting paper infused with liquid LSD. The delivery method gained popularity following the banning of the hallucinogen LSD in the late 1960s. The use of graphics on blotter sheets originated as an underground art form in the early 1970s, sometimes to help identify the dose, maker, or batch of LSD. WP

LSD art

LSD art is any art or visual displays inspired by psychedelic experiences and hallucinations known to follow the ingestion of LSD (also known colloquially as acid). Artists and scientists have been interested in the effect of LSD on drawing and painting since it first became available for legal use and general consumption.[116][117] WP

Music

The influence of LSD in the realms of music and art became pronounced in the 1960s, especially through the Acid Tests and related events involving bands like the Grateful Dead, Jefferson Airplane, and Big Brother and the Holding Company. San Francisco-based artists such as Rick Griffin, Victor Moscoso, and Wes Wilson contributed to this movement through their psychedelic poster and album art. The Grateful Dead, in particular, became central to the culture of "Deadheads", with their music heavily influenced by LSD.[118] WP

In the United Kingdom, Michael Hollingshead, reputed for introducing LSD to various artists and musicians like Storm Thorgerson, Donovan, Keith Richards, and members of the Beatles, played a significant role in the drug's proliferation in the British art and music scene. Despite LSD's illegal status since 1966, it was widely used by groups including the Beatles, the Rolling Stones, and the Moody Blues. Their experiences influenced works such as the Beatles' Sgt. Pepper's Lonely Hearts Club Band and Cream's Disraeli Gears, featuring psychedelic-themed music and artwork.[119] WP

Psychedelic music of the 1960s often sought to replicate the LSD experience, incorporating exotic instrumentation, electric guitars with effects pedals, and elaborate studio techniques. Artists and bands used instruments such as sitars and tablas and employed studio effects such as backward tape, panning, and phasing. Songs such as John Prine's "Illegal Smile" and the Beatles' "Lucy in the Sky with Diamonds" have been associated with LSD, although the latter's authors denied such claims.[120–123] WP

Contemporary artists influenced by LSD include Keith Haring in the visual arts, various electronic dance music creators, and the jam band Phish. The 2018 Leo Butler play All You Need is LSD is inspired by the author's interest in the history of LSD.[124–127] WP

Legal status

The United Nations Convention on Psychotropic Substances of 1971 mandates that signing parties, including the United States, Australia, New Zealand, and most of Europe, prohibit LSD. Enforcement of these laws varies by country. The convention allows medical and scientific research with LSD.[128] WP

Australia

In Australia, LSD is classified as a Schedule 9 prohibited substance under the Poisons Standard (February 2017), indicating it may be abused or misused and its manufacture, possession, sale, or use should be prohibited except for approved research purposes. In Western Australia, the Misuse of Drugs Act 1981 provides guidelines for possession and trafficking of substances like LSD.[129][130] WP

Canada

In Canada, LSD is listed under Schedule III of the Controlled Drugs and Substances Act (CDSA). Unauthorized possession and trafficking of the substance can lead to significant legal penalties.[131] WP

United kingdom

In the United Kingdom, LSD is a Class A drug under the Misuse of Drugs Act 1971, making unauthorized possession and trafficking punishable by severe penalties. The Runciman Report and Transform Drug Policy Foundation have made recommendations and proposals regarding the legal regulation of LSD and other psychedelics.[132][133] WP

United states

In the United States, LSD is classified as a Schedule I controlled substance under the Controlled Substances Act of 1970, making its manufacture, possession, and distribution illegal without a DEA license. The law considers LSD to have a high potential for abuse, no legitimate medical use, and to be unsafe even under medical supervision. The US Supreme Court case Neal v. United States (1995) clarified the sentencing guidelines related to LSD possession.[134][135] WP

Oregon decriminalized personal possession of small amounts of drugs, including LSD, in February 2021, and California has seen legislative efforts to decriminalize psychedelics.[136] WP

Mexico

Mexico decriminalized the possession of small amounts of drugs, including LSD, for personal use in 2009. The law specifies possession limits and establishes that possession is not a crime within designated quantities.[137] WP

Czech republic

In the Czech Republic, possession of "amount larger than small" of LSD is criminalized, while possession of smaller amounts is a misdemeanor. The definition of "amount larger than small" is determined by judicial practice and specific regulations.[138][139] WP

Production

An active dose of LSD is very minute, allowing a large number of doses to be synthesized from a comparatively small amount of raw material. Twenty-five kilograms of precursor ergotamine tartrate can produce 5–6 kg of pure crystalline LSD; this corresponds to around 50–60 million doses at 100 μg. Because the masses involved are so small, concealing and transporting illicit LSD is much easier than smuggling cocaine, cannabis, or other illegal drugs.[140] WP

Manufacturing LSD requires laboratory equipment and experience in the field of organic chemistry. It takes two to three days to produce 30 to 100 grams of pure compound. It is believed that LSD is not usually produced in large quantities, but rather in a series of small batches. This technique minimizes the loss of precursor chemicals in case a step does not work as expected. Ali Altaft, the lead chemist at the University of Okara, in Punjab, Pakistan, performed the synthesis of LSD on video.[140][141] WP

Forms

LSD is produced in crystalline form and is then mixed with excipients or redissolved for production in ingestible forms. Liquid solution is either distributed in small vials or, more commonly, sprayed onto or soaked into a distribution medium. Historically, LSD solutions were first sold on sugar cubes, but practical considerations forced a change to tablet form. Appearing in 1968 as an orange tablet measuring about 6 mm across, "Orange Sunshine" acid was the first largely available form of LSD after its possession was made illegal. Tim Scully, a prominent chemist, made some of these tablets, but said that most "Sunshine" in the USA came by way of Ronald Stark, who imported approximately thirty-five million doses from Europe.[142] WP⚠ Part of this sentence could not be copied from the source. Open the source to read it in full.

Over some time, tablet dimensions, weight, shape and concentration of LSD evolved from large (4.5–8.1 mm diameter), heavyweight (≥150 μg), round, high concentration (90–350 μg/tab) dose units to small (2.0–3.5 mm diameter) lightweight (as low as 4.7 μg/tab), variously shaped, lower concentration (12–85 μg/tab, average range 30–40 μg/tab) dose units. LSD tablet shapes have included cylinders, cones, stars, spacecraft, and heart shapes. The smallest tablets became known as "Microdots".[143] WP

After tablets came "computer acid" or "blotter paper LSD", typically made by dipping a preprinted sheet of blotting paper into an LSD/water/alcohol solution. More than 200 types of LSD tablets have been encountered since 1969, and more than 350 blotter paper designs have been observed since 1975. About the same time as blotter paper, LSD came "Windowpane" (AKA "Clearlight"), which contained LSD inside a thin gelatin square a quarter of an inch (6 mm) across. LSD has been sold under a wide variety of often short-lived and regionally restricted street names, including Acid, Trips, Uncle Sid, Blotter, Lucy, Alice and doses, as well as names that reflect the designs on the sheets of blotter paper. Authorities have encountered the drug in other forms—including powder or crystal, and capsule.[142–146] WP

Blotters

Blotter art designs printed on blotter paper can identify dose strengths, different batches, or makers.[147] WP

On the other hand, blotters without art may be considered safer by some, since there is no guarantee that the printer ink used in clandestine production is edible or non-toxic for long-term exposure, and it is also possible for unscrupulous dealers to mimic reputable blotter art designs to boost sales. WP

Distribution

LSD manufacturers and traffickers in the United States can be categorized into two groups: A few large-scale producers and an equally limited number of small, clandestine chemists, consisting of independent producers who, operating on a comparatively limited scale, can be found throughout the country.[148][149] WP

As a group, independent producers are of less concern to the Drug Enforcement Administration than the large-scale groups because their product reaches only local markets.[75] WP

Many LSD dealers and chemists describe a religious or humanitarian purpose that motivates their illicit activity. Nicholas Schou's book Orange Sunshine: The Brotherhood of Eternal Love and Its Quest to Spread Peace, Love, and Acid to the World describes one such group, the Brotherhood of Eternal Love. The group was a major American LSD trafficking group in the late 1960s and early 1970s.[150] WP

In the second half of the 20th century, dealers and chemists loosely associated with the Grateful Dead like Owsley Stanley, Nicholas Sand, Karen Horning, Sarah Maltzer, "Dealer McDope", and Leonard Pickard played an essential role in distributing LSD.[118] WP

Mimics

Since 2005, law enforcement in the United States and elsewhere has seized several chemicals and combinations of chemicals in blotter paper which were sold as LSD mimics, including DOB, a mixture of DOC and DOI, 25I-NBOMe, and a mixture of DOC and DOB. Many mimics are toxic in comparatively small doses, or have extremely different safety profiles. Many street users of LSD are often under the impression that blotter paper, which is actively hallucinogenic, can only be LSD because that is the only chemical with low enough doses to fit on a small square of blotter paper. While it is true that LSD requires lower doses than most other hallucinogens, blotter paper is capable of absorbing a much larger amount of material. The DEA performed a chromatographic analysis of blotter paper containing 2C-C which showed that the paper contained a much greater concentration of the active chemical than typical LSD doses, although the exact quantity was not determined. Blotter LSD mimics can have relatively small dose squares; a sample of blotter paper containing DOC seized by Concord, California police had dose markings approximately 6 mm apart. Several deaths have been attributed to 25I-NBOMe.[151–160] WP

Notable individuals

Some notable individuals have commented publicly on their experiences with LSD. Some of these comments date from the era when it was legally available in the US and Europe for non-medical uses. Others pertain to psychiatric treatment in the 1950s and 1960s. Still others describe experiences with illegal LSD, obtained for philosophic, artistic, therapeutic, spiritual, or recreational purposes.[161][162] WP

• W. H. Auden, the poet, said, "I myself have taken mescaline once and L.S.D. once. Aside from a slight schizophrenic dissociation of the I from the Not-I, including my body, nothing happened at all." He also said, "LSD was a complete frost. … What it does seem to destroy is the power of communication. I have listened to tapes done by highly articulate people under LSD, for example, and they talk absolute drivel. They may have seen something interesting, but they certainly lose either the power or the wish to communicate." He also said, "Nothing much happened but I did get the distinct impression that some birds were trying to communicate with me."[163][164][165] WP
• James Cameron, the Canadian filmmaker, has said he experimented with LSD during his college years.[166] WP
• Daniel Ellsberg, an American peace activist, says he has had several hundred experiences with psychedelics.[167] WP
• Richard Feynman, a notable physicist at California Institute of Technology, tried LSD during his professorship at Caltech. Feynman largely sidestepped the issue when dictating his anecdotes; he mentions it in passing in the "O Americano, Outra Vez" section.[168][169] WP
• Jerry Garcia stated in a July 3, 1989 interview for Relix Magazine, in response to the question "Have your feelings about LSD changed over the years?" "They haven't changed much. My feelings about LSD are mixed. It's something that I both fear and that I love at the same time. I never take any psychedelic, have a psychedelic experience, without having that feeling of, "I don't know what's going to happen." In that sense, it's still fundamentally an enigma and a mystery."[170] WP
• Bill Gates implied in an interview with Playboy that he tried LSD during his youth.[171] WP
• Aldous Huxley, author of Brave New World, became a user of psychedelics after moving to Hollywood. He was at the forefront of the counterculture's use of psychedelic drugs, which led to his 1954 work The Doors of Perception. Dying from cancer, he asked his wife on 22 November 1963 to inject him with 100 μg of LSD. He died later that day.[172] WP
• Steve Jobs, co-founder and former CEO of Apple Inc., said, "Taking LSD was a profound experience, one of the most important things in my life."[173] WP
• Ernst Jünger, German writer and philosopher, throughout his life had experimented with drugs such as ether, cocaine, and hashish; and later in life he used mescaline and LSD. These experiments were recorded comprehensively in Annäherungen (1970, Approaches). The novel Besuch auf Godenholm (1952, Visit to Godenholm) is clearly influenced by his early experiments with mescaline and LSD. He met with LSD inventor Albert Hofmann and they took LSD together several times. Hofmann's memoir LSD, My Problem Child describes some of these meetings.[68] WP
• In a 2004 interview, Paul McCartney said that The Beatles' songs "Day Tripper" and "Lucy in the Sky with Diamonds" were inspired by LSD trips. Nonetheless, John Lennon consistently stated over the course of many years that the fact that the initials of "Lucy in the Sky with Diamonds" spelled out L-S-D was a coincidence (he stated that the title came from a picture drawn by his son Julian) and that the band members did not notice until after the song had been released, and Paul McCartney corroborated that story. John Lennon, George Harrison, and Ringo Starr also used the drug, although McCartney cautioned that "it's easy to overestimate the influence of drugs on the Beatles' music."[122][174][175] WP
• Michel Foucault had an LSD experience with Simeon Wade in Death Valley and later wrote "it was the greatest experience of his life, and that it profoundly changed his life and his work." According to Wade, as soon as he came back to Paris, Foucault scrapped the second History of Sexuality's manuscript, and totally rethought the whole project.[176][177][178] WP
• Kary Mullis is reported to credit LSD with helping him develop DNA amplification technology, for which he received the Nobel Prize in Chemistry in 1993.[179] WP
• Carlo Rovelli, an Italian theoretical physicist and writer, has credited his use of LSD with sparking his interest in theoretical physics.[180] WP
• Oliver Sacks, a neurologist famous for writing best-selling case histories about his patients' disorders and unusual experiences, talks about his own experiences with LSD and other perception altering chemicals, in his book, Hallucinations.[181] WP
• Alexander Shulgin, American chemist, told Albert Hofmann that he preferred LSD to 2C-B.[161][162] WP
• Matt Stone and Trey Parker, creators of the TV series South Park, claimed to have shown up at the 72nd Academy Awards, at which they were nominated for Best Original Song, under the influence of LSD.[182] WP

Pharmacology

Pharmacodynamics

LSD is a serotonergic psychedelic and acts as a non-selective serotonin receptor modulator. It binds with high affinity to most of the serotonin receptors. The psychedelic effects of LSD are thought to be mediated specifically by activation of the serotonin 5-HT2A receptor. However, the role of other serotonin receptors and targets in the effects of LSD cannot be ruled out and may be considered likely. Uniquely among serotonergic psychedelics, LSD also shows potentially significant affinity for the dopamine receptors, albeit much lower than for most of the serotonin receptors.[19][34][198][199] WP

LSD binds to most serotonin receptor subtypes except for the serotonin 5-HT₃ and 5-HT₄ receptors. However, some of these serotonin receptors may not be affected at typical brain concentrations of LSD. In humans, recreational doses of LSD may affect serotonin 5-HT1A, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT5A, and 5-HT₆ receptors. Although not present in humans, serotonin 5-HT5B receptors found in rodents also have high affinity for LSD. The psychedelic effects of LSD are attributed to activation of 5-HT2A receptors. Many but not all serotonin 5-HT2A receptor agonists are psychedelics, and serotonin 5-HT2A receptor antagonists block the psychedelic effects of LSD. The drug exhibits pronounced functional selectivity or biased agonism at the serotonin 5-HT2A and 5-HT2C receptors in that it activates the signal transduction enzyme phospholipase A2 (PLA2) instead of activating the enzyme phospholipase C (PLC) as the endogenous ligand serotonin does, among other differences.[19][57][200–204] WP

Exactly how LSD produces its effects is unknown, but it is thought that it may work in part by increasing glutamate release in the cerebral cortex and therefore excitation in this area, specifically in layer V. LSD, like many other drugs of recreational use, has been shown to activate DARPP-32-related pathways. The drug enhances dopamine D₂ receptor protomer recognition and signaling of D₂–5-HT2A heteromeric receptor complexes, which may contribute to its psychotropic effects. LSD has been shown to have low affinity for histamine H₁ receptors, displaying antihistamine effects, although the significance of this at doses used in humans is unknown. David E. Nichols has suggested that there may be a pharmacological basis for some bad trips with LSD, with this thought to be related to LSD's metabolite 13-hydroxy-LSD, a highly potent dopamine D₄ receptor agonist.[57][205–210] WP

LSD is a biased agonist that induces a conformation in serotonin 5-HT₂ receptors that preferentially recruits β-arrestin over activating G proteins. It also has an exceptionally long residence time when bound to serotonin receptors lasting hours, consistent with the long-lasting effects of LSD despite its relatively rapid clearance. In rodents, LSD levels are undetectable by 8 hours post-dosing, yet LSD continues to produce partial interoceptive effects (54% responding) at this time point. A crystal structure of the serotonin 5-HT2B receptor bound to LSD reveals an extracellular loop that forms a "lid" over the diethylamide end of the binding cavity and "traps" LSD in the binding pocket, which explains the slow rate of LSD unbinding from serotonin receptors. The related lysergamide lysergic acid amide (LSA) that lacks the diethylamide moiety is far less potent in comparison. Moreover, a specific residue in the binding pocket is partially responsible for the prolonged action of LSD, and this residue is found in the human protein but not in the receptors of rodents.[193][211][212][213] WP

LSD is an extraordinarily potent psychoactive drug and is among the most potent psychedelics known in humans. The very high potency of LSD in producing psychedelic-like effects is also the case in animals, including rodents and monkeys. It is unclear why LSD is so potent. The affinity and activational potency of LSD at the human serotonin 5-HT2A receptor in vitro is unremarkable compared to other psychedelics such as DOI and DOB. There is no evidence for its greater potency being related to pharmacokinetics or metabolism. It appears that the N,N-diethylamide moiety of LSD fits into a sterically constrained region of the serotonin 5-HT2A receptor that specifically accommodates this moiety.[34][57][214–218] WP

LSD, like other psychedelics, has been found to increase the expression of genes related to synaptic plasticity and hence to have psychoplastogenic effects. This appears to be mediated by serotonin 5-HT2A receptor agonism. LSD has also been reported to act as a highly potent positive allosteric modulator of the tropomyosin receptor kinase B (TrkB), one of the receptors of brain-derived neurotrophic factor (BDNF). However, subsequent studies failed to reproduce these findings and instead found no interaction of LSD with TrkB.[219–222] WP

There appears to be no significant acute tolerance to the subjective effects of LSD. Hence, its duration appears to be dictated by pharmacokinetics rather than by pharmacodynamics. This is in contrast to MDMA, which shows marked acute tolerance and a duration of effects that is shorter than its elimination half-life.[34][223] WP

The cryo-EM structures of the serotonin 5-HT2A receptor with LSD, as well as with various other psychedelics and serotonin 5-HT2A receptor agonists, have been solved and published by Bryan L. Roth and colleagues.[224][225] WP

Mechanisms of action

Neuroimaging studies using resting state fMRI recently suggested that LSD changes the cortical functional architecture. These modifications spatially overlap with the distribution of serotonergic receptors. In particular, increased connectivity and activity were observed in regions with high expression of 5-HT2A receptor, while a decrease in activity and connectivity was observed in cortical areas that are dense with 5-HT1A receptor. Experimental data suggest that subcortical structures, particularly the thalamus, play a synergistic role with the cerebral cortex in mediating the psychedelic experience. LSD, through its binding to cortical 5-HT2A receptors, may enhance excitatory neurotransmission along frontostriatal projections and, consequently, reduce thalamic filtering of sensory stimuli towards the cortex. This phenomenon appears to involve ventral, intralaminar, and pulvinar nuclei selectively.[226][227][228] WP

Absorption

The oral bioavailability of LSD was crudely estimated as approximately 71% using previous data on intravenous administration of LSD. The sample was equally divided between male and female subjects. There were no significant sex differences observed in the pharmacokinetics of LSD. In a subsequent higher-quality 2025 study, the oral bioavailability of LSD was about 80%.[229–233] WP

The pharmacokinetics of LSD were not properly determined until 2015, which is not surprising for a drug with the kind of low-μg potency that LSD possesses. In a sample of 16 healthy subjects, a single mid-range 200 μg oral dose of LSD was found to produce mean maximal concentrations of 4.5 ng/mL at a median of 1.5 hours (range 0.5–4 hours) post-administration.[229][230] WP

A large meal before taking LSD has been found to result in circulating levels that were 50% lower than on an empty stomach.[20] WP

Distribution

In terms of distribution, it is estimated that only about 1 to 1.5% of the drug reaches the brain both in animals and humans. Following a typical 100 μg dose in humans, this would be about 1 μg that is distributed into the brain. LSD levels in different brain areas have been found to vary in monkeys. Levels were equal in blood, cerebral cortex, cerebellum, and brainstem, whereas levels were 1.5 times higher in the thalamus and extrapyramidal system, 2 to 3 times higher in the hypothalamus and limbic system, 2 to 5 times higher in the auditory and visual cortex, 5 to 7 times higher in the posterior pituitary and pineal gland, and 10 times higher in the anterior pituitary gland. These varying concentrations in different brain areas may explain the specific profile or balance of psychedelic effects of LSD. Bodily distribution of LSD has also been studied.[20][215][234][235] WP

It has been said that there is a peculiar 40-minute lag before onset of the psychedelic effects of LSD when it is administered intravenously. This has been said to be related to time-dependent interactions of LSD with the serotonin 5-HT2A receptor. However, contradicting the preceding claims, other sources have stated that intravenous injection of LSD results in onset of effects within a few minutes. In a 2025 pharmacokinetic study comparing oral and intravenous LSD, the onset orally was about 45 minutes and the onset by intravenous injection was about 2.5 minutes. In addition, intrathecal injection (intraspinal injection) is reported to have a virtually instantaneous onset of action. However, in the 2025 study, time to maximal effects was about 2.5 hours orally and about 1.2 hours intravenously. In an earlier 2016 study, intravenous LSD effects similarly peaked after about 1.7 hours. For comparison, intravenous dimethyltryptamine (DMT) given as a bolus has been found to produce maximal effects after about 2 minutes and intravenous psilocybin given over 60 seconds produces peak effects after about 4 minutes. Doses of LSD are said to be similar by oral and injectable routes, with the exception of intrathecal injection, in which the dose is reduced to about one-third of usual.[1][19][20][215][218][232][236][237] WP

The plasma protein binding of LSD in humans is unknown, but it is 65 to 90% bound to plasma proteins in guinea pigs.[20] WP

Metabolism

The metabolites of LSD include 2-oxo-3-hydroxy-LSD (O-H-LSD), 2-oxo-LSD, lysergic acid ethylamide (LAE), lysergic acid ethyl-2-hydroxyethylamide (LEO), nor-LSD, 13-hydroxy-LSD, 14-hydroxy-LSD, and the glucuronide conjugates of the 13- and 14-hydroxylated metabolites, among other possible metabolites. The major metabolite of LSD is O-H-LSD. Levels of O-H-LSD in urine have been found to be 4 to 40 times higher than those of LSD, indicating extensive metabolism of LSD into this compound. It is formed by cytochrome P450 enzymes, although the specific enzymes involved are unknown, and O-H-LSD's potential pharmacology is little-studied. However, it was found to have profoundly reduced activity at the serotonin 5-HT₂ receptors relative to LSD in vitro. Little is known about the specific enzymes responsible for the formation of LSD metabolites. LSD is not metabolized by monoamine oxidase (MAO) enzymes.[210][229][230][238–242] WP

Elimination

Only 1% of the drug was eliminated in urine unchanged, whereas 13% was eliminated as O-H-LSD within 24 hours.[229][230] WP

Aghajanian and Bing (1964) found LSD had an elimination half-life of only 175 minutes (about 3 hours); however, using more accurate techniques, Papac and Foltz (1990) reported that 1 μg/kg oral LSD given to a single male volunteer had an apparent plasma half-life of 5.1 hours, with a peak plasma concentration of 5 ng/mL at 3 hours post-dose. In a more modern 2015 study, concentrations of LSD decreased following first-order kinetics with a half-life of 3.6 ± 0.9 hours and a terminal half-life of 8.9 ± 5.9 hours. A 2026 review found half-lives ranging from 3.0 to 4.3 hours in different studies.[200][229][230][231][243] WP

LSD has a longer half-life of on average 8 hours in CYP2D6 poor metabolizers or people taking CYP2D6 inhibitors due to slower metabolism.[244] WP

Miscellaneous

The acute effects of LSD normally last between 6 and 12 hours depending on dose, tolerance, and age. In a modern study, the effects of the dose of LSD given lasted for up to 12 hours and were closely correlated with the concentrations of LSD present in circulation over time, with no acute tolerance observed.[20][229][230][245] WP

Detection

LSD can be detected in concentrations larger than approximately 10% in a sample using Ehrlich's reagent and Hofmann's reagent. However, detecting LSD in human tissues is more challenging due to its active dose being significantly lower (in micrograms) compared to most other drugs (in milligrams).[246] WP

LSD may be quantified in urine for drug testing programs, in plasma or serum to confirm poisoning in hospitalized victims, or in whole blood for forensic investigations. The parent drug and its major metabolite are unstable in biofluids when exposed to light, heat, or alkaline conditions, necessitating protection from light, low-temperature storage, and quick analysis to minimize losses. Maximum plasma concentrations are typically observed 1.4 to 1.5 hours after oral administration of 100 μg and 200 μg, respectively, with a plasma half-life of approximately 2.6 hours (ranging from 2.2 to 3.4 hours among test subjects).[247][248] WP

Due to its potency in microgram quantities, LSD is often not included in standard pre-employment urine or hair analyses. However, advanced liquid chromatography–mass spectrometry methods can detect LSD in biological samples even after a single use.[246][249] WP

Receptor binding · Wikipedia

Activities of LSD

Every row cites [19][183–197]

Chemistry

Formula

C20H25N3O PC

CAS number

50-37-3 PC

Molar mass (g/mol)

323.4 PC

IUPAC name (computed by PubChem)

(6aR,9R)-N,N-diethyl-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide PC

SMILES

CCN(CC)C(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C PC

InChIKey

VAYOSLLFUXYJDT-RDTXWAMCSA-N PC

PubChem CID

5761

Pop culture

No references added yet.

References

1. Journal / agency Nichols, David E. Psychedelics. Pharmacological Reviews. 2016. doi:10.1124/pr.115.011478
2. Journal / agency Agonistic activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors
3. Journal / agency Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium
4. Journal / agency Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans
5. Journal / agency LSD toxicity: a suspected cause of death
6. Journal / agency Influence of naloxone on the effects of LSD in monkeys
7. Journal / agency Coma, hyperthermia and bleeding associated with massive LSD overdose. A report of eight cases
8. Journal / agency Ascorbic acid antagonizes the behavioural effects of LSD in cats
9. Journal / agency Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner
10. Journal / agency New Onset LSD Flashback Syndrome Triggered by the Initiation of SSRIs
11. Journal / agency LSD and tryptamine effects on sleep/wakefulness and electrocorticogram patterns in intact cats
12. Journal / agency Characterization of behavioral and endocrine effects of LSD on zebrafish
13. Journal / agency Drug dreams in mescaline and LSD addiction
14. Journal / agency Response of cluster headache to psilocybin and LSD
15. Journal / agency LSD flashback syndrome exacerbated by selective serotonin reuptake inhibitor antidepressants in adolescents
16. Journal / agency Metabolism of lysergic acid diethylamide (LSD) to 2-oxo-3-hydroxy LSD (O-H-LSD) in human liver microsomes and cryopreserved human hepatocytes
17. Journal / agency LSD-induced entropic brain activity predicts subsequent personality change
18. Journal / agency Lysergide
19. Journal / agency Holze F, Singh N, Liechti ME, D'Souza DC. Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile. Biol Psychiatry Cogn Neurosci Neuroimaging. May 2024. doi:10.1016/j.bpsc.2024.01.007 · PMID 38301886
20. Journal / agency Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A. The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther. 2008. doi:10.1111/j.1755-5949.2008.00059.x · PMID 19040555 · PMC6494066
21. Other What are hallucinogens?. January 2016
22. Journal / agency Polito V, Liknaitzky P. Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research. Journal of Psychopharmacology. August 2024. doi:10.1177/02698811241254831 · PMID 38877715 · PMC11311906
23. Harm reduction site LSD profile (chemistry, effects, other names, synthesis, mode of use, pharmacology, medical use, control status)
24. Other Gershon L. How LSD Went From Research to Religion. 19 July 2016
25. Journal / agency Liechti ME, Dolder PC, Schmid Y. Alterations of consciousness and mystical-type experiences after acute LSD in humans. Psychopharmacology. May 2017. doi:10.1007/s00213-016-4453-0 · PMID 27714429 · PMC5420386
26. Journal / agency Griffiths RR, Hurwitz ES, Davis AK, Johnson MW, Jesse R. Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT. PLOS ONE. 2019-04-23. doi:10.1371/journal.pone.0214377 · PMID 31013281 · PMC6478303
27. Journal / agency Preller KH, Burt JB, Ji JL, Schleifer CH, Adkinson BD, Stämpfli P, Seifritz E, Repovs G, Krystal JH, Murray JD, Vollenweider FX, Anticevic A. Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor. eLife. October 2018. doi:10.7554/eLife.35082 · PMID 30355445 · PMC6202055
28. Journal / agency Girn M, Roseman L, Bernhardt B, Smallwood J, Carhart-Harris R, Spreng RN. Serotonergic psychedelic drugs LSD and psilocybin reduce the hierarchical differentiation of unimodal and transmodal cortex. NeuroImage. 2022. doi:10.1016/j.neuroimage.2022.119220 · PMID 35483649
29. Journal / agency Leptourgos P, Fortier-Davy M, Carhart-Harris R, Corlett PR, Dupuis D, Halberstadt AL, Kometer M, Kozakova E, LarØi F, Noorani TN, Preller KH, Waters F, Zaytseva Y, Jardri R. Hallucinations Under Psychedelics and in the Schizophrenia Spectrum: An Interdisciplinary and Multiscale Comparison. Schizophrenia Bulletin. December 2020. doi:10.1093/schbul/sbaa117 · PMID 32944778 · PMC7707069
30. Journal / agency Holze F, Vizeli P, Ley L, Müller F, Dolder P, Stocker M, Duthaler U, Varghese N, Eckert A, Borgwardt S, Liechti ME. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology. February 2021. doi:10.1038/s41386-020-00883-6 · PMID 33059356 · PMC8027607
31. Journal / agency Sulstarova A, Scheuerlein L, Monari S, Seragnoli F, Gabriel T, Preller K, Böge K, Sentissi O, Kaiser S, Solmi M, Kirschner M, Sabé M. Treatment approaches and efficacy in psychedelic-induced psychosis: A systematic review. Asian Journal of Psychiatry. August 2025. doi:10.1016/j.ajp.2025.104604 · PMID 40614615
32. Journal / agency Halpern JH, Lerner AG, Passie T. A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPD. 2018. doi:10.1007/7854_2016_457 · PMID 27822679
33. Other Commonly Abused Drugs Charts. 2 July 2018
34. Journal / agency Nichols DE. Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD). ACS Chemical Neuroscience. October 2018. doi:10.1021/acschemneuro.8b00043 · PMID 29461039
35. Journal / agency Chwelos N, Blewett DB, Smith CM, Hoffer A. Use of d-lysergic acid diethylamide in the treatment of alcoholism. Quarterly Journal of Studies on Alcohol. September 1959. doi:10.15288/qjsa.1959.20.577 · PMID 13810249
36. Other United States Congress House Committee on Interstate and Foreign Commerce Subcommittee on Public Health and Welfare. Increased Controls Over Hallucinogens and Other Dangerous Drugs. 1968
37. Other Terry K. FDA Opens the Door to Clinical Use of LSD. 2024-03-26
38. Other National Institute on Drug Abuse. Hallucinogens
39. Journal / agency Yockey RA, Vidourek RA, King KA. Trends in LSD use among US adults: 2015–2018. Drug and Alcohol Dependence. July 2020. doi:10.1016/j.drugalcdep.2020.108071 · PMID 32450479
40. Journal / agency Grumann, Christina, et al. Pharmacokinetics and subjective effects of 1P-LSD in humans after oral and intravenous administration. Drug Testing and Analysis. January 2016. doi:10.1002/dta.2821
41. Journal / agency https://pubmed.ncbi.nlm.nih.gov/40418105/
42. Harm reduction site LSD: Interactions. November 18, 2003
43. Journal / agency Bonson, Katherine R.; Murphy, Dennis L. Alterations in responses to LSD in humans associated with chronic administration of monoamine oxidase inhibitors or lithium. Behavioural Brain Research. 1995. doi:10.1016/0166-4328(96)00102-7 · PMID 8788508
44. Harm reduction site Tripsit Factsheets - LSD
45. Journal / agency Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. Dose-independent occurrence of seizure with tramadol. Journal of Medical Toxicology. 2009. doi:10.1007/BF03161089 · PMID 19415589 · PMC3550327
46. Journal / agency Fisher, D. D.; Ungerleider, J. T. Grand mal seizures following ingestion of LSD. California Medicine. 1967. PMID 4962683 · PMC1502729
47. Other Nayak, S., Gukasyan, N., Barrett, F. S., Erowid, E., Erowid, F., Griffiths, R. R. Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures: an analysis of online psychedelic experience reports. 2021
48. Harm reduction site wanderlei. A Nice Little Trip to the Hospital: Lithium & LSD
49. Harm reduction site MissDja1a. Having a Seizure and Passing Out: Lithium & LSD
50. Forum (anecdotal) throwaway_naut. Please Read: a cautionary tale concerning LSD. 2014
51. Journal / agency Sandeep M Nayak, Natalie Gukasyan, Frederick S Barrett , Earth Erowid , Fire Erowid , Roland R Griffiths. Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports
52. Harm reduction site freshboi88. I Was Only on One Dose
53. Harm reduction site YouWerentYouAnymore. Brought My Worst Thoughts to Life
54. Journal / agency Otto Simonsson, Peper S. Hendricks, Richard Chambers, Walter Osika, Simon B. Goldberg. Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics
55. Journal / agency Edwards, C., Van Gerpen, S., & Anand, V. New-Onset Seizures in an Adolescent Following Use of LSD while on Low-Dose Lithium Therapy: A Case Study. (2024)
56. Journal / agency Umemura, Y., Andrew, T. A., Jacobs, V. L., Giustini, A. J., Lewis, L. D., & Filiano, J. J. Fatal 251-NBOMe Intoxication: A New Recreational Risk. Academic Forensic Pathology
57. Journal / agency Nichols, David E. Hallucinogens. Pharmacology & Therapeutics. 2004. doi:10.1016/j.pharmthera.2003.11.002
58. Harm reduction site Does LSD have any medical uses?
59. Journal / agency Balestrieri, A. Acquired and Crossed Tolerance to Mescaline, LSD-25, and BOL-148. Archives of General Psychiatry. 1 September 1959. doi:10.1001/archpsyc.1959.03590030063008
60. Journal / agency Isbell, H. Studies on Lysergic Acid Diethylamide (LSD-25): 1. Effects in Former Morphine Addicts and Development of Tolerance During Chronic Intoxication. A.M.A. Archives of Neurology & Psychiatry. 1 November 1956. doi:10.1001/archneurpsyc.1956.02330290012002
61. Other Freedman, D. X. Hallucinogens, neurochemical, behavioral, and clinical perspectives. 1984
62. Journal / agency Buchborn, T., Grecksch, G., Dieterich, D. C., Höllt, V. Tolerance to Lysergic Acid Diethylamide. 2016. doi:10.1016/B978-0-12-800212-4.00079-0
63. Journal / agency Halpern, J. H.; Pope Jr, H. G. Hallucinogen persisting perception disorder: what do we know after 50 years?. Drug and Alcohol Dependence. 2003. doi:10.1016/S0376-8716(02)00306-X · PMID 12609692
64. Harm reduction site Lysergic acid diethylamide
65. Journal / agency Hofmann A. LSD Ganz Persönlich. MAPS. Summer 1969
66. Other Nogrady T, Weaver DF. Medicinal Chemistry: A Molecular and Biochemical Approach. 2005
67. Harm reduction site Nichols D. Hypothesis on Albert Hofmann's Famous 1943 "Bicycle Day". May 24, 2003
68. Other Hofmann, Albert. LSD, My Problem Child. 1980
69. Other Hofmann A. History Of LSD
70. Journal / agency Gach J. History of Psychiatry and Medical Psychology. 2008. doi:10.1007/978-0-387-34708-0_12
71. Other Michael Horowitz. Interview: Albert Hofmann. July 1976
72. Journal / agency Stoll A, Hofmann A. Partialsynthese von Alkaloiden vom Typus des Ergobasins. (6. Mitteilung über Mutterkornalkaloide). Helvetica Chimica Acta. 3 May 1943. doi:10.1002/hlca.19430260326
73. Journal / agency Stoll WA. 11. Lysergsäure-diäthylamid, ein Phantastikum aus der Mutterkorngruppe. Schweizer Archiv für Neurologie und Psychiatrie. 1947
74. Journal / agency Stoll W. Ein neues, in sehr kleinen Mengen wirksames Phantastikum. Schweizer Archiv für Neurologie und Psychiatrie. 1949
75. Other LSD in the United States. Oct 1995
76. Other Henderson LA, Glass WJ. LSD: Still with us after all these years. 1994
77. Other Brecher EM. How LSD was popularized. 1972
78. Other Applebaum A. Did The Death Of Communism Take Koestler And Other Literary Figures With It?. 26 January 2010
79. Other Out-Of-Sight! SMiLE Timeline
80. Other Veysey LR. The Communal Experience: Anarchist and Mystical Communities in Twentieth-Century America. 1978
81. Harm reduction site Convention On Psychotropic Substances, 1971
82. Other Poisons Standard October 2015
83. Other https://www.health.act.gov.au/about-our-health-system/population-health/drug-law-reform
84. Other Bundesrecht konsolidiert: Gesamte Rechtsvorschrift für Suchtmittelgesetz
85. Other RESOLUÇÃO DA DIRETORIA COLEGIADA - RDC N° 130, DE 2 DE DEZEMBRO DE 2016
86. Other Schedule III
87. Other Droga, Psihotropnih Tvari I Biljaka Iz Kojih Se Može Dobiti Droga Te Tvari Koje Se Mogu Uporabiti Za Izradu Droga. January 20, 2016
88. Other Benjamin Cunningham. New drug guidelines are Europe’s most liberal. December 23, 2009
89. Other Samlet liste over euforiserende stoffer opført på bilag 1 til bekendtgørelsen om euforiserende stoffer nr. 557 af 31. maj 2011 og stoffer reguleret herefter via ændringsbekendtgørelser. June 13, 2018
90. Other Gesetz über den Verkehr mit Betäubungsmitteln: Anlage I
91. Other Vierte Verordnung über die den Betäubungsmitteln gleichgestellten Stoffe
92. Other Gesetz über den Verkehr mit Betäubungsmitteln: § 29
93. Other Tabella I
94. Other 麻薬及び向精神薬取締法
95. Other Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem
96. Other Règlement grand-ducal du 26 mars 1974 établissant la liste des stupéfiants
97. Other Opiumwet. January 1, 2020
98. Other Forskrift om narkotika (narkotikaforskriften). September 1, 2020
99. Other Glenn Greenwald. Drug Decriminalization in Portugal: Lessons for Creating Fair and Successful Drug Policies. April 2, 2009
100. Other Постановление Правительства РФ от 30.06.1998 N 681 "Об утверждении перечня наркотических средств, психотропных веществ и их прекурсоров, подлежащих контролю в Российской Федерации" (с изменениями и дополнениями)
101. Other Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien
102. Other Läkemedelsverkets författningssamling
103. Other Part I: Class A Drugs
104. Other Controlled Substances: by CSA Schedule. August 21, 2019
105. Wikipedia Wykaz środków odurzających i substancji psychotropowych. 2022
106. Harm reduction site United States Congress. Staggers-Dodd Bill, Public Law 90-639. October 24, 1968
107. Other Gasser P. Psycholytic Therapy with MDMA and LSD in Switzerland. 1994
108. Other Feuer W. Oregon becomes first state to legalize magic mushrooms as more states ease drug laws in 'psychedelic renaissance'. November 4, 2020
109. Other DeRogatis J. Turn On Your Mind: Four Decades of Great Psychedelic Rock. 2003
110. Other Gilliland J. Show 41 – The Acid Test: Psychedelics and a sub-culture emerge in San Francisco. [Part 1]: UNT Digital Library. 1969
111. Other Hicks M. Sixties Rock: Garage, Psychedelic, and Other Satisfactions Music in American Life. 2000
112. Other Mann J. Turn on and Tune in: Psychedelics, Narcotics and Euphoriants. 2009
113. Other Taylor M. OBITUARY — Ron Thelin. 1996-03-22
114. Journal / agency Davis JC. The business of getting high: head shops, countercultural capitalism, and the marijuana legalization movement. The Sixties. January 2015. doi:10.1080/17541328.2015.1058480
115. Other Conners P. White Hand Society - The Psychedelic Partnership of Timothy Leary and Allen Ginsberg. 2010
116. Journal / agency Schmid Y, Enzler F, Gasser P, Grouzmann E, Preller KH, Vollenweider FX, Brenneisen R, Müller F, Borgwardt S. Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects. Biological Psychiatry. 2015-10-15. doi:10.1016/j.biopsych.2014.11.015 · PMID 25575620
117. Other Stafford PG, Golightly BH. LSD — The Problem-Solving Psychedelic
118. Other Jarnow J. Heads: A Biography of Psychedelic America. 2016
119. Other Gilmore M. Beatles' Acid Test: How LSD Opened the Door to 'Revolver'. August 25, 2016
120. Other Rubin R, Melnick JP. Immigration and American Popular Culture: an Introduction. 2007
121. Other Prown P, Newquist HP, Eiche JF. Legends of Rock Guitar: the Essential Reference of Rock's Greatest Guitarists. 1997
122. Other Sheff D. All We Are Saying: The Last Major Interview with John Lennon and Yoko Ono. 2000
123. Other Thompson T. The New Far-Out Beatles. 16 June 1967
124. Other Haring K. Keith Haring: Journey of the Radiant Baby. 2006
125. Other Daisy Jones. Why Certain Drugs Make Specific Genres Sound So Good. 5 June 2017
126. Other Kendall Deflin. Phishin' With Matisyahu: How LSD "Turned My Entire World Inside Out". 22 June 2017
127. Other How LSD influenced Western culture. October 17, 2018
128. Harm reduction site Final act of the United Nations Conference. 1971
129. Other Poisons Standard. July 2016
130. Other Misuse of Drugs Act 1981. 18 November 2015
131. Other Canadian government. Controlled Drugs and Substances Act. 1996
132. Other Drugs and the law: Report of the inquiry into the Misuse of Drugs Act 1971. 2000
133. Other After the War on Drugs: Blueprint for Regulation. 2009
134. Other Orange Book: List of Controlled Substances and Regulated Chemicals (January 2026). January 2026
135. Other https://www.law.cornell.edu/supct/html/94-9088.ZO.html. 1996
136. Other Jaeger K. California Lawmakers Approve Bill To Legalize Psychedelics Possession In Committee. 2021-06-29
137. Other Ley de Narcomenudeo. 17 October 2009
138. Other Explanatory Report to Act No. 112/1998 Coll., which amends the Act No. 140/1961 Coll., the Criminal Code, and the Act No. 200/1990 Coll., on misdemeanors. 1998
139. Other Supreme Court of the Czech Republic. 6 Tdo 156/2010 [NS 7078/2010]. 25 February 2012
140. Other DEA. LSD Manufacture – Illegal LSD Production. 2007
141. Other Maravelias P. Willy Myco Just Released the First-Ever Video Demonstrating How to Synthesize LSD. 2024-12-18
142. Other Stafford P. Psychedelics Encyclopaedia. 1992
143. Other Laing RR, Beyerstein BL, Siegel JA. Hallucinogens: A Forensic Drug Handbook. 2003
144. Harm reduction site Honig D. Frequently Asked Questions
145. Other Street Terms: Drugs and the Drug Trade. April 5, 2005
146. Other DEA. Photo Library (page 2). 2008
147. Other Sfetcu N. Health & Drugs: Disease, Prescription & Medication. 2014
148. Other MacLean JR, Macdonald DC, Ogden F, Wilby E. The Use of LSD in Psychotherapy and Alcoholism. 1967
149. Other Ditman KS, Bailey JJ. A program for the treatment of alcoholism: LSD, malvaria, and nicotinic acid
150. Other Schou N. Orange Sunshine: The Brotherhood of Eternal Love and Its Quest to Spread Peace, Love, and Acid to the World. 2010
151. Journal / agency United States Drug Enforcement Administration. LSD Blotter Acid Mimic Containing 4-Bromo-2,5-dimethoxy-amphetamine (DOB) Seized Near Burns, Oregon. Microgram Bulletin. October 2005
152. Journal / agency United States Drug Enforcement Administration. Intelligence Alert – Blotter Acid Mimics (Containing 4-Bromo-2,5-Dimethoxy-Amphetamine (DOB)) in Concord, California. Microgram Bulletin. November 2006
153. Journal / agency United States Drug Enforcement Administration. Unusual "Rice Krispie Treat"-Like Balls Containing Psilocybe Mushroom Parts in Warren County, Missouri. Microgram Bulletin. March 2008
154. Other Iversen L. Temporary Class Drug Order Report on 5-6APB and NBOMe compounds. May 29, 2013
155. Journal / agency United States Drug Enforcement Administration. "Spice" – Plant Material(s) Laced With Synthetic Cannabinoids or Cannabinoid Mimicking Compounds. Microgram Bulletin. March 2009
156. Journal / agency United States Drug Enforcement Administration. Bulk Marijuana in Hazardous Packaging in Chicago, Illinois. Microgram Bulletin. November 2005
157. Journal / agency United States Drug Enforcement Administration. SMALL HEROIN DISKS NEAR GREENSBORO, GEORGIA. Microgram Bulletin. December 2007
158. Harm reduction site Erowid. 25I-NBOMe (2C-I-NBOMe) Fatalities / Deaths
159. Other Hastings D. New drug N-bomb hits the street, terrifying parents, troubling cops. May 6, 2013
160. Other Feehan C. Powerful N-Bomb drug – responsible for spate of deaths internationally – responsible for hospitalisation of six in Cork. January 21, 2016
161. Other Famous LSD users
162. Other People on psychedelics
163. Journal / agency Mason D. Review: Awe for Auden. The Hudson Review. Autumn 2015
164. Other Auden WH. W. H. Auden at Swathmore; An hour of questions and answers with Auden. 15 November 1971
165. Other MacMonagle N. A Master of Memorable speech. 17 February 2007
166. Other The Impossible Reality of James Cameron. 2010-01-10
167. Other Meyer A. Daniel Ellsberg Talks Psychedelics, Consciousness and World Peace. 2022-01-24
168. Other Feynman RP. Surely You're Joking, Mr. Feynman!: Adventures of a Curious Character. 1985
169. Other Gleick J. Genius: The Life and Science of Richard Feynman. 1992
170. Other Alderson J. Q&A with Jerry Garcia: Portrait of an Artist as a Tripper. April 20, 2010
171. Other The Bill Gates Interview. July 1994
172. Other Colman D. Aldous Huxley's LSD Death Trip. October 2011
173. Other Bosker B. The Steve Jobs Reading List: The Books And Artists That Made The Man. 21 October 2011
174. Other Is 'Lucy in the Sky with Diamonds' Code for LSD?. 1998-02-15
175. Other Matus V. The Truth Behind "LSD". June 2004
176. Other When Michel Foucault Tripped on Acid in Death Valley and Called It "The Greatest Experience of My Life". September 1975
177. Other Penner J. Blowing The Philosopher's Fuses: Michel Foucault's LSD Trip in The Valley of Death. June 17, 2019
178. Other Wade S. Foucault in California: [A True Story-–Wherein the Great French Philosopher Drops Acid in the Valley of Death]. 2019
179. Other Harrison A. LSD: The Geek's Wonder Drug?. 2006-01-16
180. Other Higgins C. 'There is no such thing as past or future': physicist Carlo Rovelli on changing how we think about time. 2018-04-14
181. Other Sacks O. Hallucinations. 2012
182. Other Bose SD. When Trey Parker and Matt Stone went to the Oscars on LSD Swapnil Dhruv Bose. December 27, 2021
183. Other PDSP Database
184. Other Liu T. BindingDB BDBM21342 (4R,7R)-N,N-diethyl-6-methyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),2,9,12,14-pentaene-4-carboxamide::CHEMBL263881::LSD::LSD 25::LSD,(+)::LSD,l-::Lysergic Acid Diethylamide::Lysergic Acid Diethylamide Tartrate::US20240166618, Compound LSD::[3H]-LSD::d-Isolysergic acid amide
185. Journal / agency Ray TS. Psychedelics and the human receptorome. PLOS ONE. February 2010. doi:10.1371/journal.pone.0009019 · PMID 20126400 · PMC2814854
186. Journal / agency Rickli A, Luethi D, Reinisch J, Buchy D, Hoener MC, Liechti ME. Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs). Neuropharmacology. December 2015. doi:10.1016/j.neuropharm.2015.08.034 · PMID 26318099
187. Journal / agency Rickli A, Moning OD, Hoener MC, Liechti ME. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur Neuropsychopharmacol. August 2016. doi:10.1016/j.euroneuro.2016.05.001 · PMID 27216487
188. Journal / agency Luethi D, Trachsel D, Hoener MC, Liechti ME. Monoamine receptor interaction profiles of 4-thio-substituted phenethylamines (2C-T drugs). Neuropharmacology. May 2018. doi:10.1016/j.neuropharm.2017.07.012 · PMID 28720478
189. Journal / agency Eshleman AJ, Forster MJ, Wolfrum KM, Johnson RA, Janowsky A, Gatch MB. Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function. Psychopharmacology (Berl). March 2014. doi:10.1007/s00213-013-3303-6 · PMID 24142203 · PMC3945162
190. Journal / agency Janowsky A, Eshleman AJ, Johnson RA, Wolfrum KM, Hinrichs DJ, Yang J, Zabriskie TM, Smilkstein MJ, Riscoe MK. Mefloquine and psychotomimetics share neurotransmitter receptor and transporter interactions in vitro. Psychopharmacology (Berl). July 2014. doi:10.1007/s00213-014-3446-0 · PMID 24488404 · PMC4097020
191. Journal / agency Wsół A. Cardiovascular safety of psychedelic medicine: current status and future directions. Pharmacol Rep. December 2023. doi:10.1007/s43440-023-00539-4 · PMID 37874530 · PMC10661823
192. Journal / agency Egan C, Grinde E, Dupre A, Roth BL, Hake M, Teitler M, Herrick-Davis K. Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors. Synapse. February 2000. doi:10.1002/(SICI)1098-2396(200002)35:2<144::AID-SYN7>3.0.CO;2-K · PMID 10611640
193. Journal / agency Wacker D, Wang S, McCorvy JD, Betz RM, Venkatakrishnan AJ, Levit A, Lansu K, Schools ZL, Che T, Nichols DE, Shoichet BK, Dror RO, Roth BL. Crystal Structure of an LSD-Bound Human Serotonin Receptor. Cell. January 2017. doi:10.1016/j.cell.2016.12.033 · PMID 28129538 · PMC5289311
194. Other McCorvy JD. Mapping the binding site of the 5-HT2A receptor using mutagenesis and ligand libraries: Insights into the molecular actions of psychedelics. 16 January 2013
195. Journal / agency Porter RH, Benwell KR, Lamb H, Malcolm CS, Allen NH, Revell DF, Adams DR, Sheardown MJ. Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells. Br J Pharmacol. September 1999. doi:10.1038/sj.bjp.0702751 · PMID 10498829 · PMC1571597
196. Journal / agency Gainetdinov RR, Hoener MC, Berry MD. Trace Amines and Their Receptors. Pharmacol Rev. July 2018. doi:10.1124/pr.117.015305 · PMID 29941461
197. Journal / agency Simmler LD, Buchy D, Chaboz S, Hoener MC, Liechti ME. In Vitro Characterization of Psychoactive Substances at Rat, Mouse, and Human Trace Amine-Associated Receptor 1. J Pharmacol Exp Ther. April 2016. doi:10.1124/jpet.115.229765 · PMID 26791601
198. Journal / agency Halberstadt AL, Geyer MA. Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology. September 2011. doi:10.1016/j.neuropharm.2011.01.017 · PMID 21256140 · PMC3110631
199. Journal / agency Marona-Lewicka D, Thisted RA, Nichols DE. Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis. Psychopharmacology. July 2005. doi:10.1007/s00213-005-2183-9 · PMID 15723230
200. Journal / agency Aghajanian GK, Bing OH. Persistence of lysergic acid diethylamide in the plasma of human subjects. Clinical Pharmacology and Therapeutics. 1964. doi:10.1002/cpt196455611 · PMID 14209776
201. Journal / agency Nelson DL. 5-HT5 receptors. Current Drug Targets. CNS and Neurological Disorders. February 2004. doi:10.2174/1568007043482606 · PMID 14965244
202. Journal / agency Moreno JL, Holloway T, Albizu L, Sealfon SC, González-Maeso J. Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists. Neuroscience Letters. April 2011. doi:10.1016/j.neulet.2011.01.046 · PMID 21276828 · PMC3064746
203. Journal / agency Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M, Mailman RB. Functional selectivity and classical concepts of quantitative pharmacology. The Journal of Pharmacology and Experimental Therapeutics. January 2007. doi:10.1124/jpet.106.104463 · PMID 16803859
204. Journal / agency Bonniwell EM, Alabdali R, Hennessey JJ, McKee JL, Cavalco NG, Lammers JC, Moore EJ, Franchini L, Orlandi C, McCorvy JD. Serotonin 5-HT2C Receptor Signaling Analysis Reveals Psychedelic Biased Agonism. ACS Chem Neurosci. October 2025. doi:10.1021/acschemneuro.5c00647 · PMID 40944639 · PMC12629614
205. Journal / agency Aghajanian GK, Marek GJ. Serotonin and hallucinogens. Neuropsychopharmacology. August 1999. doi:10.1016/S0893-133X(98)00135-3 · PMID 10432484
206. Journal / agency Svenningsson P, Nairn AC, Greengard P. DARPP-32 mediates the actions of multiple drugs of abuse. The AAPS Journal. October 2005. doi:10.1208/aapsj070235 · PMID 16353915 · PMC2750972
207. Journal / agency Borroto-Escuela DO, Romero-Fernandez W, Narvaez M, Oflijan J, Agnati LF, Fuxe K. Hallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A heteroreceptor complexes. Biochemical and Biophysical Research Communications. January 2014. doi:10.1016/j.bbrc.2013.11.104 · PMID 24309097
208. Journal / agency Green JP, Johnson CL, Weinstein H, Maayani S. Antagonism of histamine-activated adenylate cyclase in brain by D-lysergic acid diethylamide. Proceedings of the National Academy of Sciences of the United States of America. December 1977. doi:10.1073/pnas.74.12.5697 · PMID 23536 · PMC431860
209. Journal / agency Nichols DE, Frescas S, Marona-Lewicka D, Kurrasch-Orbaugh DM. Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N, N-diethyllysergamide (LSD). Journal of Medicinal Chemistry. September 2002. doi:10.1021/jm020153s · PMID 12213075
210. Other Nichols D, Billac GB, Harbit RC, Smith JM. A Pharmacological Basis for Some Bad LSD Trips?: A 50+ Year Odyssey. 1 March 2026
211. Journal / agency Chen Q, Tesmer JJ. A Receptor on Acid. Cell. January 2017. doi:10.1016/j.cell.2017.01.012 · PMID 28129534 · PMC5520807
212. Journal / agency Roth BL, Gumpper RH. Psychedelics as Transformative Therapeutics. Am J Psychiatry. May 2023. doi:10.1176/appi.ajp.20230172 · PMID 37122272
213. Journal / agency Higgins GA, MacMillan C, de Lannoy I, Tyler C, Slassi M. Pharmacological characterisation of psilocybin and 5-MeO-DMT discriminative cues in the rat and their translational value for identifying novel psychedelics. J Psychopharmacol. August 2025. doi:10.1177/02698811251361453 · PMID 40862395
214. Journal / agency Nichols DE. Behavioral Neurobiology of Psychedelic Drugs. 2017. doi:10.1007/7854_2017_475 · PMID 28401524
215. Other Brimblecombe RW, Pinder RM. Hallucinogenic Agents. 1975
216. Journal / agency Halberstadt AL, Chatha M, Klein AK, Wallach J, Brandt SD. Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species. Neuropharmacology. May 2020. doi:10.1016/j.neuropharm.2019.107933 · PMID 31917152 · PMC9191653
217. Journal / agency Nichols DE. LSD and Its Lysergamide Cousins. The Heffter Review of Psychedelic Research. 2001
218. Journal / agency Gumpper RH, Nichols DE. Chemistry/structural biology of psychedelic drugs and their receptor(s). Br J Pharmacol. October 2024. doi:10.1111/bph.17361 · PMID 39354889
219. Journal / agency Calder AE, Hasler G. Towards an understanding of psychedelic-induced neuroplasticity. Neuropsychopharmacology. January 2023. doi:10.1038/s41386-022-01389-z · PMID 36123427 · PMC9700802
220. Journal / agency Hatzipantelis CJ, Olson DE. The Effects of Psychedelics on Neuronal Physiology. Annu Rev Physiol. February 2024. doi:10.1146/annurev-physiol-042022-020923 · PMID 37931171 · PMC10922499
221. Journal / agency Moliner R, Girych M, Brunello CA, Kovaleva V, Biojone C, Enkavi G, Antenucci L, Kot EF, Goncharuk SA, Kaurinkoski K, Kuutti M, Fred SM, Elsilä LV, Sakson S, Cannarozzo C, Diniz CR, Seiffert N, Rubiolo A, Haapaniemi H, Meshi E, Nagaeva E, Öhman T, Róg T, Kankuri E, Vilar M, Varjosalo M, Korpi ER, Permi P, Mineev KS, Saarma M, Vattulainen I, Casarotto PC, Castrén E. Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nat Neurosci. June 2023. doi:10.1038/s41593-023-01316-5 · PMID 37280397 · PMC10244169
222. Journal / agency Jain MK, Gumpper RH, Slocum ST, Schmitz GP, Madsen JS, Tummino TA, Suomivuori CM, Huang XP, Shub L, DiBerto JF, Kim K, DeLeon C, Krumm BE, Fay JF, Keiser M, Hauser AS, Dror RO, Shoichet B, Gloriam DE, Nichols DE, Roth BL. The polypharmacology of psychedelics reveals multiple targets for potential therapeutics. Neuron. July 2025. doi:10.1016/j.neuron.2025.06.012 · PMID 40683247
223. Other Matthias Liechti. Pharmacology of novel psychoactive substances, MDMA, and LSD. 2016
224. Journal / agency Gumpper RH, Jain MK, Kim K, Sun R, Sun N, Xu Z, DiBerto JF, Krumm BE, Kapolka NJ, Kaniskan HÜ, Nichols DE, Jin J, Fay JF, Roth BL. The structural diversity of psychedelic drug actions revealed. Nature Communications. March 2025. doi:10.1038/s41467-025-57956-7 · PMID 40108183 · PMC11923220
225. Other Gumpper RH, DiBerto J, Jain M, Kim K, Fay J, Roth BL. Structures of Hallucinogenic and Non-Hallucinogenic Analogues of the 5-HT2A Receptor Reveals Molecular Insights into Signaling Bias. September 2022
226. Journal / agency Singleton SP, Luppi AI, Carhart-Harris RL, Cruzat J, Roseman L, Nutt DJ, Deco G, Kringelbach ML, Stamatakis EA, Kuceyeski A. Receptor-informed network control theory links LSD and psilocybin to a flattening of the brain's control energy landscape. Nat Commun. Oct 2022. doi:10.1038/s41467-022-33578-1 · PMID 36192411 · PMC9530221
227. Journal / agency Delli Pizzi S, Chiacchiaretta P, Sestieri C, Ferretti A, Onofrj M, Della Penna S, Roseman L, Timmermann C, Nutt DJ, Carhart-Harris RL, Sensi SL. Spatial Correspondence of LSD-Induced Variations on Brain Functioning at Rest With Serotonin Receptor Expression. Biol Psychiatry Cogn Neurosci Neuroimaging. July 2023. doi:10.1016/j.bpsc.2023.03.009 · PMID 37003409
228. Journal / agency Delli Pizzi S, Chiacchiaretta P, Sestieri C, Ferretti A, Tullo MG, Della Penna S, Martinotti G, Onofrj M, Roseman L, Timmermann C, Nutt DJ, Carhart-Harris RL, Sensi SL. LSD-induced changes in the functional connectivity of distinct thalamic nuclei. NeuroImage. Dec 2023. doi:10.1016/j.neuroimage.2023.120414 · PMID 37858906
229. Journal / agency Dolder PC, Schmid Y, Haschke M, Rentsch KM, Liechti ME. Pharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans. The International Journal of Neuropsychopharmacology. June 2015. doi:10.1093/ijnp/pyv072 · PMID 26108222 · PMC4772267
230. Journal / agency Mucke HA. From Psychiatry to Flower Power and Back Again: The Amazing Story of Lysergic Acid Diethylamide. Assay and Drug Development Technologies. July 2016. doi:10.1089/adt.2016.747 · PMID 27392130
231. Journal / agency Zhang T, Lin C, Wang X. Overcoming Pharmacokinetic and Peripheral Safety Challenges in Psychedelic Therapies: The Promise of Advanced Drug Delivery Systems. ACS Pharmacology & Translational Science. 25 May 2026. doi:10.1021/acsptsci.6c00146 · PMID 42312173 · PMC13270451
232. Journal / agency Arikci D, Holze F, Mueller L, Vizeli P, Rudin D, Luethi D, Hysek CM, Liechti ME. Absolute Oral Bioavailability and Bioequivalence of LSD Base and Tartrate in a Double-Blind, Placebo-Controlled, Crossover Study. Clinical Pharmacology and Therapeutics. May 2025. doi:10.1002/cpt.3726 · PMID 40418105 · PMC12355019
233. Journal / agency Holze F, Mueller L, Vizeli P, Luethi D, Rudin D, Hysek C, Liechti M, Arikci D. Oral LSD base and tartrate bioequivalence and absolute bioavailability in healthy participants. Neuroscience Applied. 2024. doi:10.1016/j.nsa.2024.105132
234. Journal / agency Snyder SH, Reivich M. Regional localization of lysergic acid diethylamide in monkey brain. Nature. March 1966. doi:10.1038/2091093a0 · PMID 4958949
235. Journal / agency Herian M. Handbook of Substance Misuse and Addictions. 2022. doi:10.1007/978-3-030-92392-1_131
236. Journal / agency Shulgin AT. Profiles of Psychedelic Drugs: LSD. J Psychedelic Drugs. 1980. doi:10.1080/02791072.1980.10471571 · PMID 7420434
237. Journal / agency Carhart-Harris RL, Muthukumaraswamy S, Roseman L, Kaelen M, Droog W, Murphy K, Tagliazucchi E, Schenberg EE, Nest T, Orban C, Leech R, Williams LT, Williams TM, Bolstridge M, Sessa B, McGonigle J, Sereno MI, Nichols D, Hellyer PJ, Hobden P, Evans J, Singh KD, Wise RG, Curran HV, Feilding A, Nutt DJ. Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proc Natl Acad Sci U S A. April 2016. doi:10.1073/pnas.1518377113 · PMID 27071089 · PMC4855588
238. Journal / agency Dolder P. The Pharmacology of d-Lysergic Acid Diethylamide (LSD). 2017. doi:10.5451/UNIBAS-006786123
239. Journal / agency Meyer MR, Maurer HH. Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse. Pharmacogenomics. February 2011. doi:10.2217/pgs.10.171 · PMID 21332315
240. Journal / agency Maurer HH, Meyer MR. Metabolism of Drugs and Other Xenobiotics. 18 April 2012. doi:10.1002/9783527630905.ch16
241. Journal / agency Luethi D, Hoener MC, Krähenbühl S, Liechti ME, Duthaler U. Cytochrome P450 enzymes contribute to the metabolism of LSD to nor-LSD and 2-oxo-3-hydroxy-LSD: Implications for clinical LSD use. Biochem Pharmacol. June 2019. doi:10.1016/j.bcp.2019.04.013 · PMID 30981875
242. Journal / agency Rached G, Campana A, Fiani D, Nguyen C, Van den Eynde V, Gillman PK, Barnett BS. Safety and Efficacy of Monoamine Oxidase Inhibitors in Patients Who Use Psychoactive Substances: Potential Drug Interactions and Substance Use Disorder Treatment Data. CNS Drugs. January 2026. doi:10.1007/s40263-025-01256-7 · PMID 41546846
243. Journal / agency Papac DI, Foltz RL. Measurement of lysergic acid diethylamide (LSD) in human plasma by gas chromatography/negative ion chemical ionization mass spectrometry. Journal of Analytical Toxicology. May–June 1990. doi:10.1093/jat/14.3.189 · PMID 2374410
244. Journal / agency Vogt SB, Liechti ME. Psychedelics in Psychiatry. 2025. doi:10.1016/bs.irn.2025.02.003 · PMID 40541320
245. Other Shulgin AT, Shulgin A. TiHKAL: The Continuation. 1997
246. Journal / agency Appel JB, Whitehead WE, Freedman DX. Motivation and the behavioral effects of LSD. Psychonomic Science. July 1968. doi:10.3758/BF03331322
247. Other R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 12th edition, Biomedical Publications, Foster City, CA, 2020, pp. 1197–1199
248. Journal / agency Dolder PC, Schmid Y, Steuer AE, Kraemer T, Rentsch KM, Hammann F, Liechti ME. Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects. Clinical Pharmacokinetics. October 2017. doi:10.1007/s40262-017-0513-9 · PMID 28197931 · PMC5591798
249. Journal / agency Jiaming Z, Xin W, Jiali Z, Hang R, Yunli Z, Ping X. Concentrations of LSD, 2-oxo-3-hydroxy-LSD, and iso-LSD in hair segments of 18 drug abusers. Forensic Science International. March 2023. doi:10.1016/j.forsciint.2023.111578 · PMID 36753839

Text and values on this page are quoted from PsychonautWiki (CC BY-SA 4.0), Wikipedia (CC BY-SA 4.0), TripSit factsheets, PubChem (public domain). Each value links to the exact revision it came from.